Xlife Sciences AG (XLS.SW)
Swiss · CHF · Healthcare · Biotechnology
CHF 8.70 (+0.00%) as of
Key statistics
- Market cap
- 50.17M
- Forward P/E
- -2.96
- EPS (TTM)
- -32.31
- Dividend yield
- 0.00%
- 52-week range
- 8.22 – 26.80
- Beta
- 0.50
- Revenue (TTM)
- 397.23k
- Profit margin
- 0.00%
- Analyst target
- CHF 31.00
- Volume
- 1.87k
About Xlife Sciences AG
Xlife Sciences AG focuses on the development and commercialization of research projects in the life sciences sector. The company's project covers technology platforms, biotechnology/therapies, medical technology, and artificial intelligence/digital health areas that focuses on identifying new therapeutic approaches and biomarkers for common diseases based on human genetic data; and offers clinical research services. It also develops novel treatment options in specific indication areas; focuses in the areas of medical technology to develop innovative methods for diagnosing illnesses and/or patient monitoring; and deploys artificial intelligence to improve diagnostic methods and/or processes in the field of biotechnology. Xlife Sciences AG was founded in 2019 and is headquartered in Zurich, Switzerland.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- Zurich, Switzerland
- Employees
- 20
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.